Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
DUBLIN - Investment firm Citadel Group has disclosed a 1.08% interest in Mural Oncology plc, according to a regulatory filing published Tuesday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 187,896 shares representing a long position in the Dublin-based oncology company. This includes 175,596 owned or controlled shares and 12,300 shares through stock-settled derivatives.
The filing also reveals Citadel maintains a short position of 206,100 shares, or approximately 1.18% of Mural Oncology’s outstanding stock.
According to the disclosure, Citadel executed multiple transactions on October 27, purchasing a total of 39,482 common shares at prices ranging from $2.09 to $2.10 per share. On the same day, the firm sold 24,020 shares at similar price points.
The regulatory document also details Citadel’s options positions, including purchased call options with various strike prices from $2.50 to $7.50 and expiration dates extending to January 2027.
The disclosure was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires public disclosure when an entity holds interests representing 1% or more in a company that could be involved in a potential takeover situation.
Mural Oncology’s shares trade on the Irish Stock Exchange with the ISIN code IE000LK2BOB4. The filing indicates no indemnity arrangements or voting agreements exist between Citadel and other parties related to these securities.
This information was provided through a Form 8.3 filing submitted to the Regulatory Information Service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.